08 Jan Despite Better Chemotherapy, US Women Choosing More Rather Than Less TNBC Surgery
Posted at 20:32h
in Author Interviews, Breast Cancer, Brigham & Women's - Harvard, JAMA, Surgical Research
MedicalResearch.com Interview with:
[caption id="attachment_52688" align="alignleft" width="200"]
Dr. Golshan[/caption]
Mehra Golshan, MD, MBA
Dr. Abdul Mohsen & Sultana Al-Tuwaijri Distinguished Chair
Surgical OncologyDirector of Breast Surgical Oncology Fellowship
Associate Professor, Harvard Medical School
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Triple negative breast cancer is an aggressive form of breast cancer that often requires chemotherapy. In this study we provided neoadjuvant chemotherapy with or without a PARP inhibitor and showed that many women who were originally ineligible for breast conservation (lumpectomy) became eligible after treatment.
If lumpectomy was tried it was usually successful. Many more women in the US compared to Europe and Asia chose mastectomy when lumpectomy was an option even when genetics is negative.
Dr. Breyer[/caption]
Benjamin N. Breyer MD, MAS, FACS
Associate Professor
Departments of Urology and Epidemiology and Biostatistics
University of California, San Francisco
Vice-Chair of Urology
Chief of Urology, Zuckerberg San Francisco General Hospital and Trauma Center
Director, UCSF Male Genitourinary Reconstruction and Trauma Surgery Fellowship
MedicalResearch.com: What is the background for this study?
Response: There has been a large increase in upright scooter usage among adults as a mode of transportation. It's convenient for commuters and may encourage greater use of public transit leading to less car traffic in cities.
Dr. Cohen[/caption]
Pieter A. Cohen, MD
Department of Medicine, Cambridge Health Alliance
Somerville, Massachusetts
Harvard Medical School
Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: There has been increasing interest in the use of over-the-counter supplements to help improve memory and cognitive function. However, prior
Dr. Emily Parker Hyle[/caption]
Emily Parker Hyle, M.D.
Assistant Professor of Medicine
Massachusetts General Hospital
MedicalResearch.com: What is the background for this study?
Response: We found that many children who were planning to travel internationally were eligible for MMR vaccination prior to departure but often did not receive it - especially if they were aged 6 months to 6 years. That is because most children do not routinely receive their first dose of MMR till 12-15 months of age and their second dose of MMR till 4-6 years of age. However, ACIP recommendations are different for children who are traveling internationally. The risk of being infected with measles is much higher outside of the US, so it is recommended that children older than 1 year have had 2 MMR vaccinations and that children 6-12 months receive 1 MMR vaccination prior to travel. MMR vaccination is a safe and effective way to greatly reduce the risk of measles infection.
Dr. Perumalswami[/caption]
Chithra R. Perumalswami, MD, MSc
Research Fellow
Center for Bioethics & Social Sciences in Medicine
University of Michigan
[caption id="attachment_51839" align="alignleft" width="133"]